Dr. Garrett is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
33 Whiting Hill Rd
Ste 21
Brewer, ME 04412Phone+1 207-973-7478Fax+1 207-973-8707
Education & Training
- Vanderbilt University Medical CenterResidency, Internal Medicine, 1989 - 1992
- Boston University School of MedicineClass of 1989
Certifications & Licensure
- ME State Medical License 1995 - 2025
- TN State Medical License 1993 - 1997
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2011-2014
Clinical Trials
- T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) Start of enrollment: 2013 May 01
Publications & Presentations
PubMed
- 2 citationsAdjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Corre...Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, Chau Dang, Denise A Yardley
Journal of Clinical Oncology. 2024-11-01 - 73 citationsAdjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical TrialSara M. Tolaney, Nabihah Tayob, Chau T. Dang, Denise A. Yardley, Steven J. Isakoff
Journal of Clinical Oncology. 2021-06-02 - 9 citationsCardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TB...Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, Chau Dang, Denise A Yardley
NPJ Breast Cancer. 2022-02-16
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: